Crohn's and Colitis 360 : Impact Factor & More
eISSN: 2631-827XpISSN: 2631-827X
Open AccessShare this on:
Key Metrics
CiteScore 
1
SNIP
0.35
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Crohn's and Colitis 360 Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | OXFORD UNIV PRESS |
| Language | English |
| Frequency | Quarterly |
| Article Processing Charges | USD 2975 |
| Publication Time | 12 |
| Editorial Review Process | Double anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Crohn's and Colitis Foundation |
| Frequency | Quarterly |
| Publication Start Year | 2019 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Crohn's and Colitis 360 ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Crohn's and Colitis 360
Evaluation of a Pharmacist Directed Treat to Target Approach in Patients With Inflammatory Bowel Disease Receiving Upadacitinib or Risankizumab
- 20 Apr 2026
- 1 Jan 0360
Providing care at a most vulnerable time.
- 11 Apr 2026
- 1 Jan 0360
Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease.
- 1 Apr 2026
- 1 Jan 0360
Child and parent perspectives in IBD management: a literature review and qualitative study
- 15 Mar 2026
- 1 Jan 0360
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn’s disease: results from the phase 2 SERENITY study
- 11 Mar 2026
- 1 Jan 0360
Transabdominal intestinal ultrasound versus transmural histopathological findings in severe ulcerative colitis requiring colectomy
- 7 Mar 2026
- 1 Jan 0360
Evaluation of a Pharmacist Directed Treat to Target Approach in Patients With Inflammatory Bowel Disease Receiving Upadacitinib or Risankizumab
- 20 Apr 2026
- 1 Jan 0360
Providing care at a most vulnerable time.
- 11 Apr 2026
- 1 Jan 0360
Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease.
- 1 Apr 2026
- 1 Jan 0360
Child and parent perspectives in IBD management: a literature review and qualitative study
- 15 Mar 2026
- 1 Jan 0360
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn’s disease: results from the phase 2 SERENITY study
- 11 Mar 2026
- 1 Jan 0360
Transabdominal intestinal ultrasound versus transmural histopathological findings in severe ulcerative colitis requiring colectomy
- 7 Mar 2026
- 1 Jan 0360
FAQs on Crohn's and Colitis 360
How long has Crohn's and Colitis 360 been actively publishing? 
What is the publishing frequency of Crohn's and Colitis 360?
How many articles did Crohn's and Colitis 360 publish last year?
What is the eISSN & pISSN for Crohn's and Colitis 360?
What is Citescore for Crohn's and Colitis 360?
What is SNIP score for Crohn's and Colitis 360?
Who is the publisher of Crohn's and Colitis 360?
